DeepCure, a biotechnology company leveraging AI for drug discovery, has unveiled its first development candidate, DC-9476. This third-generation BRD inhibitor targets the BD2 domain of Brd4, a key regulator of cytokine pathways implicated in autoimmune diseases.
DC-9476 exhibits promising efficacy in preclinical models of autoimmune diseases, including rheumatoid arthritis, surpassing standard therapies and enhancing the effectiveness of TNF-alpha inhibitors in combination therapy. It has also demonstrated a favorable safety profile, avoiding the thrombocytopenia associated with earlier inhibitors.
DeepCure’s AI platform, combining machine learning and physics-based tools, enables the identification of novel interaction sites and the design of diverse, synthetically feasible compounds. This approach addresses the limitations of existing therapies by targeting multiple inflammatory pathways simultaneously.
Professor Francesco Del Galdo highlights the need for more comprehensive treatments for autoimmune diseases, where targeting individual pathways has had limited success. DC-9476’s multi-pathway inhibition and excellent safety profile make it a promising candidate for addressing this unmet medical need.
DeepCure’s generative AI and physics-based drug discovery engine has played a crucial role in the development of DC-9476, validating its potential to unlock novel therapeutic options for autoimmune diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
